Literature DB >> 9463572

Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas.

I K Bukholm1, J M Nesland, R Kåresen, U Jacobsen, A L Børresen-Dale.   

Abstract

In breast carcinomas the TP53 gene is altered in 10-30% of cases. Alteration of the gene may lead to a general genomic instability, detected as deletions and/or amplifications at the gene level, and as altered expression at the mRNA and protein level. We have demonstrated a strong association between down-regulation of E-cadherin protein expression and alterations of the p53 protein, detected as TP53 gene mutation and/or protein accumulation in tumour samples from 210 patients with breast carcinomas (P < 0.001). Investigation of allelic imbalance using microsatellite markers located near the E-cadherin locus was also performed. A higher frequency of loss of heterozygosity in the microsatellite marker closest to the E-cadherin locus was observed in samples with down-regulation of E-cadherin protein expression. A higher frequency of down-regulation of the E-cadherin protein expression was found in invasive lobular carcinomas than in invasive ductal carcinomas, although this difference was of borderline significant (P = 0.084). Cases in the present series were also immunostained for cerB-2 protein overexpression. A significant association between p53 protein accumulation and cerbB-2 protein overexpression was seen (P = 0.036). The results of the present study indicate that p53 protein may play a role in regulation of E-cadherin protein expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463572     DOI: 10.1007/s004280050105

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  9 in total

1.  Excess beta-catenin promotes accumulation of transcriptionally active p53.

Authors:  A Damalas; A Ben-Ze'ev; I Simcha; M Shtutman; J F Leal; J Zhurinsky; B Geiger; M Oren
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

2.  Expression of E-Cadherin in breast carcinomas and its association with other biological markers - a prospective study.

Authors:  B Rekhi; A Bansal; D Bhatnagar; S Saxena
Journal:  Indian J Surg Oncol       Date:  2010-08-07

3.  Role of E-cadherin gene in gall bladder cancer and its precursor lesions.

Authors:  T Padma Priya; V K Kapoor; N Krishnani; Vinita Agrawal; Suraksha Agrawal
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

4.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.

Authors:  Shu-Ping Wang; Wen-Lung Wang; Yih-Leong Chang; Chen-Tu Wu; Yu-Chih Chao; Shih-Han Kao; Ang Yuan; Chung-Wu Lin; Shuenn-Chen Yang; Wing-Kai Chan; Ker-Chau Li; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Nat Cell Biol       Date:  2009-05-17       Impact factor: 28.824

5.  Expression of e-cadherin in high-risk breast cancer.

Authors:  Eugene M Howard; Stephen K Lau; Robert H Lyles; George G Birdsong; Jay N Umbreit; Ruby Kochhar
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-01       Impact factor: 4.553

6.  Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.

Authors:  C Huiping; J R Sigurgeirsdottir; J G Jonasson; G Eiriksdottir; J T Johannsdottir; V Egilsson; S Ingvarsson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

7.  Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin.

Authors:  Kate Matthews; Cheng Mee Leong; Lindsay Baxter; Emma Inglis; Kankatsu Yun; B Thomas Bäckström; John Doorbar; Merilyn Hibma
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.

Authors:  Amit Goyal; Tracey A Martin; Robert E Mansel; Wen G Jiang
Journal:  World J Surg Oncol       Date:  2008-06-11       Impact factor: 2.754

9.  The R72P P53 mutation is associated with familial breast cancer in Jewish women.

Authors:  T Ohayon; R Gershoni-Baruch; M Z Papa; T Distelman Menachem; S Eisenberg Barzilai; E Friedman
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.